Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2695089 | 0.91 | PRMT6 (0.38) | PRMT6ADORA1P2RY12BMPR1B | |
| SCHEMBL12416177 | 0.84 | PRMT6 (0.36) | PRMT6ADORA1P2RY12BMPR1B | |
| SCHEMBL769666 | 0.83 | PRMT6 (0.36) | PRMT6ADORA1P2RY12 | |
| SCHEMBL2693038 | 0.81 | PRMT6 (0.36) | PRMT6ADORA1P2RY12SMN1; SMN2BMPR1B | |
| SCHEMBL769927 | 0.80 | BMPR1B (0.41) | ADORA1P2RY12BMPR1B | |
| SCHEMBL10117328 | 0.78 | PRMT6 (0.36) | PRMT6P2RY12 | |
| SCHEMBL10117495 | 0.77 | KDM4E (0.45) | — | |
| SCHEMBL10075998 | 0.77 | PRMT6 (0.42) | PRMT6ADORA1P2RY12BMPR1B | |
| SCHEMBL26455123 | 0.77 | P2RY12 (0.38) | PRMT6ADORA1P2RY12 | |
| SCHEMBL26327190 | 0.76 | PRMT6 (0.36) | PRMT6P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130211064-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8440803-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120071645-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | ISIS PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120021515-A1 | OLIGOMERIC COMPOUNDS AND METHODS | ISIS PHARMACEUTICALS, INC. | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021515-A1 | OLIGOMERIC COMPOUNDS AND METHODS | HNRNPH1, RNASEH1, SNRPE | PRMT6 2026/4885ADORA1 3412/4885P2RY12 4807/4885 |
| US-20120071645-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | HNRNPM, POLM, RNMT | PRMT6 701/4885ADORA1 2330/4885P2RY12 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.